Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma

Bradley C. Leibovich, Yuri Sheinin, Christine M. Lohse, R. Houston Thompson, John C. Cheville, Jan Zavada, Eugene D Kwon

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Purpose: Expression of carbonic anhydrase IX (CAIX) has been reported to be an independent predictor of outcome and is being investigated as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC). We attempted to validate the prognostic utility of CAIX expression using a large cohort of ccRCC patients with long-term follow-up. Patients and Methods: We identified 730 patients with unilateral, sporadic ccRCC treated surgically between 1990 and 1999. Anti-CAIX monoclonal antibody (clone M75) was used, and tumor specimens were blindly scored for expression levels. Associations of CAIX expression with RCC death were evaluated using Cox proportional hazards regression models. Results: There were 241 RCC deaths and a median of 9.4 years of follow-up for patients still under observation. CAIX was expressed in 708 (97.0%) of the specimens; 163 tumors (22.3%) exhibited low (≤ 85% tumor cells positive) expression, and 567 (77.7%) exhibited high (> 85% tumor cells positive) expression. Univariately, low CAIX expression was associated with increased risk of RCC death relative to high expression (risk ratio = 1.65; P < .001). However, low CAIX expression was not associated with RCC death after adjusting for nuclear grade or coagulative tumor necrosis. Additionally, we observed CAIX expression in a number of extrarenal organs. Conclusion: CAIX is strongly expressed by ccRCC. Although CAIX is associated with outcome in patients with ccRCC, it is not an independent prognostic marker. Furthermore, CAIX expression is apparent in extrarenal organs. As such, exploitation of CAIX as a prognostic marker and therapeutic target merits additional consideration.

Original languageEnglish (US)
Pages (from-to)4757-4764
Number of pages8
JournalJournal of Clinical Oncology
Volume25
Issue number30
DOIs
StatePublished - Oct 20 2007
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Neoplasms
Carbonic Anhydrase IX
Proportional Hazards Models
Necrosis
Clone Cells
Odds Ratio
Observation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. / Leibovich, Bradley C.; Sheinin, Yuri; Lohse, Christine M.; Thompson, R. Houston; Cheville, John C.; Zavada, Jan; Kwon, Eugene D.

In: Journal of Clinical Oncology, Vol. 25, No. 30, 20.10.2007, p. 4757-4764.

Research output: Contribution to journalArticle

Leibovich, Bradley C. ; Sheinin, Yuri ; Lohse, Christine M. ; Thompson, R. Houston ; Cheville, John C. ; Zavada, Jan ; Kwon, Eugene D. / Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 30. pp. 4757-4764.
@article{6c86ed4a77f448c8a8fed8aa1f90c92a,
title = "Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma",
abstract = "Purpose: Expression of carbonic anhydrase IX (CAIX) has been reported to be an independent predictor of outcome and is being investigated as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC). We attempted to validate the prognostic utility of CAIX expression using a large cohort of ccRCC patients with long-term follow-up. Patients and Methods: We identified 730 patients with unilateral, sporadic ccRCC treated surgically between 1990 and 1999. Anti-CAIX monoclonal antibody (clone M75) was used, and tumor specimens were blindly scored for expression levels. Associations of CAIX expression with RCC death were evaluated using Cox proportional hazards regression models. Results: There were 241 RCC deaths and a median of 9.4 years of follow-up for patients still under observation. CAIX was expressed in 708 (97.0{\%}) of the specimens; 163 tumors (22.3{\%}) exhibited low (≤ 85{\%} tumor cells positive) expression, and 567 (77.7{\%}) exhibited high (> 85{\%} tumor cells positive) expression. Univariately, low CAIX expression was associated with increased risk of RCC death relative to high expression (risk ratio = 1.65; P < .001). However, low CAIX expression was not associated with RCC death after adjusting for nuclear grade or coagulative tumor necrosis. Additionally, we observed CAIX expression in a number of extrarenal organs. Conclusion: CAIX is strongly expressed by ccRCC. Although CAIX is associated with outcome in patients with ccRCC, it is not an independent prognostic marker. Furthermore, CAIX expression is apparent in extrarenal organs. As such, exploitation of CAIX as a prognostic marker and therapeutic target merits additional consideration.",
author = "Leibovich, {Bradley C.} and Yuri Sheinin and Lohse, {Christine M.} and Thompson, {R. Houston} and Cheville, {John C.} and Jan Zavada and Kwon, {Eugene D}",
year = "2007",
month = "10",
day = "20",
doi = "10.1200/JCO.2007.12.1087",
language = "English (US)",
volume = "25",
pages = "4757--4764",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "30",

}

TY - JOUR

T1 - Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma

AU - Leibovich, Bradley C.

AU - Sheinin, Yuri

AU - Lohse, Christine M.

AU - Thompson, R. Houston

AU - Cheville, John C.

AU - Zavada, Jan

AU - Kwon, Eugene D

PY - 2007/10/20

Y1 - 2007/10/20

N2 - Purpose: Expression of carbonic anhydrase IX (CAIX) has been reported to be an independent predictor of outcome and is being investigated as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC). We attempted to validate the prognostic utility of CAIX expression using a large cohort of ccRCC patients with long-term follow-up. Patients and Methods: We identified 730 patients with unilateral, sporadic ccRCC treated surgically between 1990 and 1999. Anti-CAIX monoclonal antibody (clone M75) was used, and tumor specimens were blindly scored for expression levels. Associations of CAIX expression with RCC death were evaluated using Cox proportional hazards regression models. Results: There were 241 RCC deaths and a median of 9.4 years of follow-up for patients still under observation. CAIX was expressed in 708 (97.0%) of the specimens; 163 tumors (22.3%) exhibited low (≤ 85% tumor cells positive) expression, and 567 (77.7%) exhibited high (> 85% tumor cells positive) expression. Univariately, low CAIX expression was associated with increased risk of RCC death relative to high expression (risk ratio = 1.65; P < .001). However, low CAIX expression was not associated with RCC death after adjusting for nuclear grade or coagulative tumor necrosis. Additionally, we observed CAIX expression in a number of extrarenal organs. Conclusion: CAIX is strongly expressed by ccRCC. Although CAIX is associated with outcome in patients with ccRCC, it is not an independent prognostic marker. Furthermore, CAIX expression is apparent in extrarenal organs. As such, exploitation of CAIX as a prognostic marker and therapeutic target merits additional consideration.

AB - Purpose: Expression of carbonic anhydrase IX (CAIX) has been reported to be an independent predictor of outcome and is being investigated as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC). We attempted to validate the prognostic utility of CAIX expression using a large cohort of ccRCC patients with long-term follow-up. Patients and Methods: We identified 730 patients with unilateral, sporadic ccRCC treated surgically between 1990 and 1999. Anti-CAIX monoclonal antibody (clone M75) was used, and tumor specimens were blindly scored for expression levels. Associations of CAIX expression with RCC death were evaluated using Cox proportional hazards regression models. Results: There were 241 RCC deaths and a median of 9.4 years of follow-up for patients still under observation. CAIX was expressed in 708 (97.0%) of the specimens; 163 tumors (22.3%) exhibited low (≤ 85% tumor cells positive) expression, and 567 (77.7%) exhibited high (> 85% tumor cells positive) expression. Univariately, low CAIX expression was associated with increased risk of RCC death relative to high expression (risk ratio = 1.65; P < .001). However, low CAIX expression was not associated with RCC death after adjusting for nuclear grade or coagulative tumor necrosis. Additionally, we observed CAIX expression in a number of extrarenal organs. Conclusion: CAIX is strongly expressed by ccRCC. Although CAIX is associated with outcome in patients with ccRCC, it is not an independent prognostic marker. Furthermore, CAIX expression is apparent in extrarenal organs. As such, exploitation of CAIX as a prognostic marker and therapeutic target merits additional consideration.

UR - http://www.scopus.com/inward/record.url?scp=36048987954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36048987954&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.12.1087

DO - 10.1200/JCO.2007.12.1087

M3 - Article

C2 - 17947723

AN - SCOPUS:36048987954

VL - 25

SP - 4757

EP - 4764

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 30

ER -